High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.
about
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomasInflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patientsPrognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysisThe Multifaceted Roles Neutrophils Play in the Tumor MicroenvironmentBiomarkers and prognostic factors for mesotheliomaGuidelines for the diagnosis and treatment of malignant pleural mesotheliomaPrognostic Importance of Controlling Nutritional Status in Patients Undergoing Curative Thoracoscopic Esophagectomy for Esophageal Cancer.Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy.Granulocyte-to-dendritic cell-ratio as marker for the immune monitoring in patients with renal cell carcinoma.Malignant pleural mesothelioma: predictors and stagingPreoperative Neutrophil-to-Lymphocyte Ratio as a New Prognostic Marker in Hepatocellular Carcinoma after Curative Resection.Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratiosLymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapyNeutrophil-lymphocyte ratio as a predictor of recurrence and progression in patients with high-grade pT1 bladder cancer.The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognosticationThe neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.Novel immunological and nutritional-based prognostic index for gastric cancer.Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South WalesKi67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.Neutrophil count is associated with survival in localized prostate cancerAdoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy.Low local blood perfusion, high white blood cell and high platelet count are associated with primary tumor growth and lung metastasis in a 4T1 mouse breast cancer metastasis model.Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma?A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer.Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular CarcinomaWhat is the normal value of the neutrophil-to-lymphocyte ratio?Nuclear-enriched abundant transcript 1 as a diagnostic and prognostic biomarker in colorectal cancer.Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinomaPretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.Association of the Preoperative Neutrophil-to-ymphocyte Count Ratio and Platelet-to-Lymphocyte Count Ratio with Clinicopathological Characteristics in Patients with Papillary Thyroid Cancer.The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesotheliomaHuman mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomesPrognostic performance of inflammation-based prognostic indices in locally advanced non-small-lung cancer treated with endostar and concurrent chemoradiotherapyBlood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor.Clinical significance of preoperative inflammatory parameters in gastric cancer patients.
P2860
Q26859274-86B54248-5F7A-4AAE-9CCB-73D3F105680DQ27009534-BC570D8C-8926-4EE9-9835-05A2D51D5673Q27022482-FEEBB6F3-1EED-420B-8C14-A539ADEE897EQ28241308-A1E6BC2D-D304-4E48-9A08-C107F8A5DD8EQ28387194-EA9E6AFC-88F9-4A5C-8C77-600A49C733DEQ28394028-D5024E62-C981-43CA-8C08-4B7AA0B16584Q30488933-06808885-4A2F-489C-9FE8-E6C893C3EC97Q33655475-C346AC38-9B86-4414-BDAF-91A6E1B56D90Q33792392-4A9E6D69-8F31-40BB-BB79-FA34AABDC180Q33871571-7A897B3C-1307-4CC0-AF81-7E3D9F37BAFFQ33912315-F55A22C0-C31B-46D9-8905-5B95E5C88E8FQ34041728-A39E3944-2099-4766-A165-C0F6D953328CQ34239292-FCE41EEF-4EB7-4C56-977E-CA43246653E1Q34608340-B0FDD55C-A0A9-4EB7-8EC3-063F5FFC35BCQ35180082-13919C8E-F208-42A1-A1FB-D230B4F079F0Q35207251-4A7A887E-5408-4609-8C11-C345D498F3FCQ35220302-4487829B-F827-4112-BC47-D49B280F595EQ35274923-1EBD704D-99D0-43C9-B465-BB1E98DC3EABQ35274955-E87F2344-2020-4F35-A680-B24284252171Q35625425-81866F04-A89D-4F27-AD58-8742A95DFAFFQ35678085-DEAB7F78-DA0A-4864-B61D-F4F178581F64Q35678741-064FA85D-EE7B-478D-9C06-888ABFE953CCQ35711576-DB529263-8ECE-4531-BCB3-A01BCB48C6A5Q35751637-9BAEC213-CB54-419E-892C-F1DC68ECFEB0Q35752854-9540742A-6BDD-4795-B779-64959E8AC9FAQ35856677-B1E2923E-A999-4EBC-9E2D-30812E38D5D8Q36027639-41ECE9D8-5F7F-4584-BC63-4567D1B69853Q36166771-85D2138D-22D7-4DD4-9CF4-244C2352AB7EQ36194925-D0CEB105-3E80-44FD-92A3-8FED465AD968Q36241444-E5B5C8F7-C1AE-49C1-A469-60F4031F13B2Q36267118-C6A2EA4A-0D60-4D09-8E2A-8890043498D4Q36345736-E4DDCF04-98A1-4D52-B608-C36BB78EE9C8Q36353298-9979582A-AC30-491E-9FC5-EB8E46D408E9Q36483161-02B3B08B-FABF-4ADC-88C3-9BC34A120574Q36489138-D2CD1D5F-1E59-43CD-918C-36D5E80A54C3Q36671963-4DE251AB-F3E9-4E30-B456-D3EEA1B72FA6Q36711060-E3F1BF90-4AE1-4E6E-90DC-5DCD9EBB9E42Q36824972-2ACC0245-0C9A-43F8-938E-94574A019103Q36979386-8BD5A49A-E314-4C6F-A8D3-A7E66D32065FQ36993466-EE530AB9-48A9-4AD4-B811-0F544DF18ECA
P2860
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
High blood neutrophil-to-lymph ...... s undergoing systemic therapy.
@en
High blood neutrophil-to-lymph ...... s undergoing systemic therapy.
@nl
type
label
High blood neutrophil-to-lymph ...... s undergoing systemic therapy.
@en
High blood neutrophil-to-lymph ...... s undergoing systemic therapy.
@nl
prefLabel
High blood neutrophil-to-lymph ...... s undergoing systemic therapy.
@en
High blood neutrophil-to-lymph ...... s undergoing systemic therapy.
@nl
P2093
P1476
High blood neutrophil-to-lymph ...... s undergoing systemic therapy.
@en
P2093
Michael J Boyer
Nick Pavlakis
Rozelle Harvie
Stephen J Clarke
Steven C H Kao
P304
P356
10.1158/1078-0432.CCR-10-2245
P407
P577
2010-10-18T00:00:00Z